As filed with the Securities and Exchange Commission on July 25, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CAN-FITE BIOPHARMA LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 26 Ben Gurion ...

公司融资与资金用途 - 公司已累计融资1.75亿美元，用于推进核心候选药物进入关键临床试验阶段 [1] - 资金支持药物生产、FDA与EMA的监管活动以及广泛的知识产权组合开发 [3] 核心候选药物研发进展 - Namodenoson（口服A3AR激动剂）正处于针对晚期肝癌的关键III期研究患者招募阶段，并展示出对肝和胰腺肿瘤细胞的选择性靶向能力 [2] - Piclidenoson（口服A3AR激动剂）正处于针对中重度银屑病的关键III期试验中 [2] - 两种候选药物在先前II期试验中显示出良好的安全性、抗癌和抗炎特性以及有前景的疗效 [3] 其他研发管线拓展 - Namodenoson正在胰腺癌中进行IIa期研究，临床前研究表明其通过调节Wnt/β-catenin、NF-κB和RAS信号通路抑制肿瘤生长 [4] - 利用Namodenoson的肝脏保护作用，针对代谢功能障碍相关脂肪性肝炎（MASH）的IIb期试验已在FDA开放IND下进行 [4] - 公司第三种候选药物CF602在治疗勃起功能障碍方面显示出疗效 [6] 商业化与合作 - 公司已签署七项商业化协议，为候选药物在获批后的未来营销做准备 [5] - 公司持续与潜在合作伙伴接洽，寻求未来签署更多商业化协议 [5] 公司技术与监管里程碑 - 公司技术平台瞄准癌症、肝脏和炎症性疾病治疗领域价值数十亿美元的市场 [6] - Namodenoson已在美国和欧洲获得孤儿药认定，并获FDA授予作为肝细胞癌（HCC）二线治疗的快速通道资格 [6] - 公司药物在迄今超过1600名患者的临床研究中显示出优异的安全性 [6]

As filed with the Securities and Exchange Commission on February 10, 2023 Registration No. 333-269485 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Can-Fite BioPharma Ltd. (Exact name of registrant as specified in its charter) | State of Israel | 2834 | Not applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organi ...

Can-Fite BioPharma Ltd. (Exact name of registrant as specified in its charter) | State of Israel | 2834 | Not applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Number) | Identification No.) | As filed with the Securities and Exchange Commission on January 31, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEME ...